Medtronic PLC $MDT Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Medtronic PLC (NYSE:MDT - Free Report) by 6.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 241,630 shares of the medical technology company's stock after acquiring an additional 13,973 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Medtronic were worth $21,695,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Integrated Wealth Concepts LLC increased its stake in shares of Medtronic by 23.3% during the first quarter. Integrated Wealth Concepts LLC now owns 52,162 shares of the medical technology company's stock worth $4,687,000 after acquiring an additional 9,868 shares during the period. Hancock Whitney Corp increased its stake in shares of Medtronic by 1.7% during the first quarter. Hancock Whitney Corp now owns 29,097 shares of the medical technology company's stock worth $2,615,000 after acquiring an additional 478 shares during the period. Edmond DE Rothschild Holding S.A. increased its stake in shares of Medtronic by 0.9% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 681,246 shares of the medical technology company's stock worth $61,217,000 after acquiring an additional 6,388 shares during the period. Clark Capital Management Group Inc. increased its stake in shares of Medtronic by 8.1% during the first quarter. Clark Capital Management Group Inc. now owns 465,985 shares of the medical technology company's stock worth $41,873,000 after acquiring an additional 34,859 shares during the period. Finally, Belmont Capital LLC acquired a new position in shares of Medtronic during the first quarter worth about $167,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Medtronic

In other news, Director William R. Jellison bought 2,500 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The shares were purchased at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the firm's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The disclosure for this sale can be found here. 0.26% of the stock is owned by corporate insiders.

Analyst Ratings Changes

MDT has been the topic of a number of recent analyst reports. Robert W. Baird boosted their price target on shares of Medtronic from $94.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 20th. Argus increased their target price on shares of Medtronic from $105.00 to $115.00 and gave the company a "buy" rating in a report on Tuesday, August 26th. Morgan Stanley reaffirmed an "overweight" rating and issued a $107.00 target price (up from $98.00) on shares of Medtronic in a report on Tuesday, July 15th. William Blair raised shares of Medtronic to a "hold" rating in a report on Friday, July 11th. Finally, Mizuho increased their target price on shares of Medtronic from $98.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $102.14.

Medtronic Stock Up 0.1%

MDT stock opened at $92.93 on Monday. The company's 50 day simple moving average is $90.97 and its 200-day simple moving average is $88.14. The firm has a market capitalization of $119.20 billion, a PE ratio of 25.60, a P/E/G ratio of 2.36 and a beta of 0.77. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $96.25. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The company's quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be given a $0.71 dividend. The ex-dividend date is Friday, September 26th. This represents a $2.84 annualized dividend and a dividend yield of 3.1%. Medtronic's dividend payout ratio is currently 78.24%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.